Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)
ArchivedNational Institutes of Health
Description
The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds.
Who can apply
- Public and State controlled institutions of higher education
Contact
NIH Grants Information<br/>grantsinfo@nih.gov
grantsinfo@nih.gov
- PostedJul 12, 2023
- ClosesOct 17, 2023
- CFDA93.242
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro